Ori Spotlight

In episode 14 of the Ori Spotlight Podcast, Jason C. Foster is joined by John Connolly, Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy, who explained why and how the industry needs to increase the accessibility of CGT for patients.

In episode 13 of the Ori Spotlight Podcast Jason C. Foster sits down with Mike Nicholson (President and Chief Operating Officer) and Matt Haines (Vice President of Manufacturing Operations) at Inceptor Bio, as they share their insights into the cell and gene therapy space.

Inceptor Bio is on a mission to cure difficult to treat cancers using next-generation cell therapy platforms. Their unique partnership model, with university oncology research programs, leverages their manufacturing resources and expert cell and gene therapy skills, to advance therapeutics into the clinic.

Mike and Matt catch up with Jason to discuss the opportunities and challenges of CGT manufacturing, bringing CGT to patients at scale and what they envision for the future of CGT.

Learn more about:

Mike Nicholson - LinkedIn | Matt Haines - LinkedIn

In Episode 12 of the Ori Spotlight Podcast, Jason C. Foster sits down with Northpond Ventures, investor in both Ori’s Series A and Series B funding. We caught up with Directors Adam Wieschhaus and Shaan Gandhi, as they share their insights into the cell and gene therapy space. 

Northpond Ventures is a $2.15 billion venture capitalist firm focused on life science, medicine, and technology; with 60 investments to date since its inception. Adam and Shaan lead their San Francisco and Boston offices respectively. 

Adam and Shaan sit down with Jason to discuss why bringing scalable cell and gene therapies to market is vital, the impact these therapies have on patients, and what excites them most about the investments made within the CGT space.

Learn more about:

In episode 11 of the Ori Spotlight Podcast we sit down with Paul Meister, Partner at Novalis LifeSciences - lead investor of Ori Biotech’s series B round - as he shares his perspectives on the potential for CGT.

In episode 10 of the Ori Spotlight Podcast we sit down with Farlan Veraitch, Co-Founder and Chief Scientific Officer at Ori Biotech. 

Farlan is an internationally recognized expert in CGT-manufacturing, with 15 years’ experience as a leading academic at University College London, pioneering innovative technologies in CGT bioprocessing. At Ori, he leads the research and development of Ori's revolutionary manufacturing technology platforms.

In the podcast, Farlan joins Jason C. Foster to share his co-founder story and explains Ori's unique approach, borne out of a desire to dramatically bring down the cost of CGTs and enable widespread patient access of these life-changing therapies.

Learn more about Farlan | https://www.linkedin.com/in/farlan-veraitch-a677112/

On episode nine of the Ori Spotlight Podcast we sat down with Qasim Rafiq, Associate Professor of Cell and Gene Therapy Bioprocessing at University College London, and Thomas Heathman, Ori's Vice President of Commercial Operations.

Qasim leads the world first MSc in Manufacturing and Commercialization of Stem Cell and Gene Therapies, and was named as one of the top 20 influential and inspirational individuals in Advanced Medicine for 2020 by The Medicine Maker. 

Together, we explore one of the most significant factors affecting the high costs of CGT: the industry's ongoing talent shortage. They discuss how the problem should be addressed, bringing together academic institutions with CGT organizations to identify the evolving expertise required, not just across scientific and clinical research teams but also in digital and technology disciplines.

Learn more about Dr. Qasim Rafiq| https://www.linkedin.com/in/qrafiq/?originalSubdomain=uk

On Ori Spotlight episode eight we sat down with Robert Preti, strategic advisor at Ori. 

Robert has an illustrious background in cell and gene therapy leading innovation as Chief Strategy Officer for Minaris as well as leading the Alliance for Regenerative Medicine (ARM) for several years as chairman. 

Joining Ori Biotech's CEO Jason C. Foster, the pair discuss where cell therapy all began, its explosion into the biopharma industry scene and why there is still a lot of work today to make sure that as many patients as possible can benefit from its life-changing possibilities.

Learn more about Robert Preti | https://www.linkedin.com/in/robert-preti-41586217/

On episode seven of the Ori Spotlight Podcast we sat down with Dr. Annalisa Jenkins, Strategic Advisor for Ori and advisor to the FDA, to discuss the changes she's seen in CGT pricing and market access models over the years. 

As board chairman for many private and public companies, Annalisa recounts how it all started and how she sees the industry evolving. She's passionate about the idea that we need to continue to embrace innovation to drive down prices while still having successful companies that can meet the needs of both their patients and shareholders.

Learn more about Dr. Annalisa Jenkins| 

Dennis Powers, Vice President of Business Development & Sales Engineering at G-CON Manufacturing joins Jason C. Foster for the new episode of the Ori Spotlight Podcast.  

Dennis explains how manufacturing powerhouse G-CON is injecting innovation right into the heart of cell and gene therapy with their prefabricated cleanrooms called PODs. 

Drawing on his wealth of experience in life sciences and biotech, Dennis also shares his predictions for the manufacturing industry from his unique vantage point.

Learn more about Dennis Powers | 

Learn more about Ori Biotech | www.oribiotech.com

Rahul Singhvi, Co-Founder and CEO at Resilience joins Jason C. Foster for the new episode of the Ori Spotlight Podcast.  With extensive experience leading vaccine technologies and biotherapeutics at Merck and Takeda, Rahul co-founded Resilience in order to create the next generation of life science manufacturing, to meet the urgent need at what is an inflection point for the biotechnology industry.

Learn more about Resilience | www.resilience.com

Learn more about Ori Biotech | www.oribiotech.com